Cadila’s arm gets USFDA’s nod for Valacyclovir Tablets

30 Dec 2017 Evaluate

Cadila Healthcare’s wholly owned subsidiary -- Zydus Pharmaceuticals (USA) has received final approval from the United States Food & Drug Administration (USFDA) to market Valacyclovir Tablets USP in strengths of 500 mg and 1 gm. The drug is indicated for the treatment of cold sores (herpes labialis), genital herpes, chickenpox and herpes zoster (shingles). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.


Zydus Lifesciences Share Price

948.70 4.45 (0.47%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.